Detailed price information for Crinetics Pharmaceuticals Inc (CRNX-Q) from The Globe and Mail including charting and trades.

(Nasdaq: CRNX) today announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH) study of investigational atumelnant, a novel, once-daily oral ...

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, announced positive topline results from an open-label, phase 2 congenital adrenal hyperplasia (CAH) study of investigational ...

Excessive hair growth can be embarrassing and frustrating. Learn the underlying causes of unwanted hair growth in women and ...

Dana Pizzuti, the Chief Medical (TASE:PMCN) and Development Officer of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), recently executed a series of stock transactions as disclosed in a recent SEC ...

(NASDAQ:NBIX) has sponsored a supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM) focusing on classic congenital adrenal hyperplasia (CAH), a rare genetic condition. The ...

Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development ...

Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...

Tokio Marine Asset Management Co. Ltd. cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.8% ...

Results: Results are available in a week. Please contact your doctor if you are not called about the result. Adrenocorticotropic Hormone (ACTH) Stimulation Test for Non-classic Congenital Adrenal ...